Key points
- In a 2026 UCLA study, creatine, the same tub sold to weightlifters, recharged dendritic cells, the immune cells that rally T cells at a tumor, and slowed cancer growth in mice.
- Dendritic cells pulled from inside tumors were making extra creatine transporter protein. Knock that transporter out and the cells survived worse and lost their knack for priming a T-cell attack.
- Keep the expectations low. This is mice plus human cells in a dish. No human trial has run, and the team says outright: do not take creatine to treat cancer.
How a coordinator cell decides a fight
Start with why dendritic cells matter, because that is the hinge of the whole paper. T cells get the credit for killing tumor cells, but they sit idle until a dendritic cell finds the threat, breaks it down, and presents it, handing out the wanted poster. No competent dendritic cell, no organised attack.
Inside a tumor, that coordinator is starving. The tumor hoards nutrients, and the immune cells trying to work there run low on fuel. The UCLA group, led by Lili Yang with co-first authors James Elsten-Brown and Elliot Kang, noticed that dendritic cells taken from inside tumors had cranked up the creatine transporter (CrT), the doorway that lets creatine into a cell, far above what dendritic cells in healthy tissue showed. Reading that as a cell reaching for backup fuel, the team cut the fuel line. Dendritic cells engineered without the transporter survived poorly, activated weakly, and primed T cells badly.
Then they ran it the other way
If removing creatine breaks the coordinator, does adding it help? The team gave daily creatine injections to mice carrying melanoma. Tumors grew more slowly. Inside them, dendritic cells turned up in greater numbers and in a more activated state, and their ATP, the molecule a cell spends to get work done, climbed. Yang put it in battery terms: creatine lets the cell store and release spare energy on demand, so it holds a steady charge even while fast-growing tumor cells are stealing the nutrients around it.
The dish work pointed the same way. Human dendritic cells from healthy donors, dosed with creatine, activated more strongly and primed T cells better. Two systems, one direction.
One honest gap: the widely circulated write-ups did not pin down the exact daily dose or duration the mice received, so this piece won’t put a number on it that the coverage didn’t.
Where this actually goes
This is a metabolism finding with a clinical hunch attached, not a treatment. The authors float two uses. Creatine could ride alongside existing immunotherapy and help it work in more people, or it could be used to build sturdier dendritic-cell cancer vaccines before they are given to a patient. Both need human trials that have not begun.
The distance between an energised mouse dendritic cell and a helped cancer patient is long, and the team does not pretend otherwise. What they have earned is a serious look at a cheap, well-tolerated supplement as an immunotherapy partner. That is a reason to run the trial. It is not a reason to raid the supplement aisle.
Sources:
- Medical News Today, “Creatine supplements may help halt cancer growth, study suggests”
- UCLA Health, “Creatine may supercharge immune cells that are key to fighting cancer”
- iScience, “Creatine uptake promotes dendritic cell activation and enhances antitumor immunity” (Elsten-Brown, Kang, Yang et al., 2026)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.